The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: Chicago, IL : American Medical Association, [2018]-
    • Subject Terms:
    • Abstract:
      Importance: It is unknown whether the triglyceride-glucose (TyG) index as a measure of insulin resistance is associated with the risk of developing end-stage kidney disease (ESKD). Because individuals who are overweight or obese often develop insulin resistance, mediation of the association between body mass index (BMI) and ESKD risk through the TyG index seems plausible but has not been investigated.
      Objective: To evaluate whether the TyG index is associated with ESKD risk and, if so, to what extent the TyG index mediates the association between BMI and ESKD.
      Design, Setting, and Participants: A total of 176 420 individuals were recruited during routine health examinations to participate in the Austrian Vorarlberg Health Monitoring and Promotion Program (VHM&PP), a prospective, population-based cohort study with participant enrollment between January 1, 1988, and June 30, 2005, and a mean follow-up of 22.7 years. Data analysis was conducted from March 1, 2020, to September 30, 2020.
      Exposures: Body mass index and the logarithmized product of fasting triglyceride and glucose concentrations (TyG index), as determined during the baseline health examination.
      Main Outcomes and Measures: End-stage kidney disease, as indicated by initiation of kidney replacement therapy, either dialysis or kidney transplantation.
      Results: Of the 176 420 participants, 94 885 were women (53.8%); mean (SD) age was 42.5 (15.4) years. During a mean (SD) follow-up of 22.7 (6.9) years, 454 (0.3%) participants developed ESKD and 35 234 (20.0%) died. In multivariable-adjusted Cox proportional hazards models, the TyG index was significantly associated with the risk of ESKD, both with (hazard ratio [HR] per 1-SD increase, 1.68; 95% CI, 1.56-1.82) and without (HR per 1-SD increase, 1.79; 95% CI, 1.66-1.93) the inclusion of BMI as a covariate. Mediation analysis using a newly proposed 2-stage regression method for survival data showed that a 5-point increase in BMI increased the risk of ESKD by 58% (HR [total association], 1.58; 95% CI, 1.43-1.75), and that 41.7% of the total association (95% CI, 31.6%-51.8%) was mediated through the TyG index (HR [indirect association], 1.21; 95% CI, 1.18-1.25).
      Conclusions and Relevance: This study found that the TyG index appeared to be associated with ESKD risk and mediates nearly half of the total association between BMI and ESKD in the general population. Public health efforts aiming at the reduction of body weight might decrease the kidney sequelae of insulin resistance and the burden of ESKD.
    • References:
      Lancet. 2015 Aug 22;386(9995):743-800. (PMID: 26063472)
      J Am Soc Nephrol. 2016 Jul;27(7):2135-47. (PMID: 26701975)
      Ann Intern Med. 2006 Jan 3;144(1):21-8. (PMID: 16389251)
      Lancet. 2016 Apr 2;387(10026):1377-1396. (PMID: 27115820)
      Int J Obes (Lond). 2018 Jun;42(5):964-973. (PMID: 29568103)
      Sci Rep. 2020 May 5;10(1):7578. (PMID: 32371883)
      Clin J Am Soc Nephrol. 2017 Jun 7;12(6):893-903. (PMID: 28522656)
      Lancet. 2013 Jul 20;382(9888):260-72. (PMID: 23727169)
      Diabetes. 1988 Dec;37(12):1595-607. (PMID: 3056758)
      J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51. (PMID: 20484475)
      JAMA. 2007 Nov 7;298(17):2038-47. (PMID: 17986697)
      Nephrol Dial Transplant. 2003 Aug;18(8):1562-7. (PMID: 12897095)
      Psychol Methods. 2013 Jun;18(2):137-50. (PMID: 23379553)
      Am J Kidney Dis. 2008 Jul;52(1):29-38. (PMID: 18511168)
      Cardiorenal Med. 2017 Dec;8(1):41-49. (PMID: 29344025)
      PLoS One. 2016 Aug 18;11(8):e0161376. (PMID: 27537361)
      Kidney Int. 2017 May;91(5):1224-1235. (PMID: 28187985)
      J Clin Invest. 2015 Jan;125(1):248-57. (PMID: 25437877)
      Epidemiology. 2015 Mar;26(2):e23-4. (PMID: 25643116)
      Am J Kidney Dis. 2016 Jan;67(1):62-9. (PMID: 26187471)
      Metab Syndr Relat Disord. 2008 Dec;6(4):299-304. (PMID: 19067533)
      Kidney Int. 2004 May;65(5):1870-6. (PMID: 15086929)
      Arch Intern Med. 2012 Nov 26;172(21):1644-50. (PMID: 23108588)
      J Clin Endocrinol Metab. 2011 Aug;96(8):2525-31. (PMID: 21593117)
      Epidemiology. 1999 Jan;10(1):37-48. (PMID: 9888278)
      Epidemiol Health. 2017 Aug 6;39:e2017035. (PMID: 29121709)
      Kidney Int. 2017 Aug;92(2):313-323. (PMID: 28341271)
      Annu Rev Public Health. 2016;37:17-32. (PMID: 26653405)
      Nat Rev Nephrol. 2017 Mar;13(3):181-190. (PMID: 28090083)
      Eur Heart J. 2003 Jun;24(11):1004-13. (PMID: 12788300)
      Kidney Int. 2014 Aug;86(2):246-50. (PMID: 24897034)
      Am J Kidney Dis. 2008 Jul;52(1):39-48. (PMID: 18440684)
      Diabetes. 1998 May;47(5):793-800. (PMID: 9588452)
      Am J Kidney Dis. 2005 Nov;46(5):871-80. (PMID: 16253727)
      Ann Intern Med. 2004 Feb 3;140(3):167-74. (PMID: 14757614)
      Lancet Diabetes Endocrinol. 2015 Sep;3(9):704-14. (PMID: 26235959)
      Epidemiology. 2011 Jul;22(4):582-5. (PMID: 21642779)
      JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714)
      PLoS One. 2016 Jul 06;11(7):e0158765. (PMID: 27383068)
      Prev Med. 2007 Oct;45(4):247-51. (PMID: 17950122)
      J Am Soc Nephrol. 2017 Dec;28(12):3429-3432. (PMID: 29054854)
      Lancet. 2015 Jan 10;385(9963):117-71. (PMID: 25530442)
      Am J Nephrol. 2017;45(3):283-291. (PMID: 28178697)
      Nat Rev Nephrol. 2016 Dec;12(12):721-737. (PMID: 27748389)
      Am J Kidney Dis. 2009 Oct;54(4):638-46. (PMID: 19515474)
      Am J Kidney Dis. 2005 Oct;46(4):587-94. (PMID: 16183412)
      Sci Rep. 2018 May 16;8(1):7729. (PMID: 29769597)
      Kidney Int. 2019 May;95(5):1225-1233. (PMID: 30898340)
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Triglycerides)
    • Publication Date:
      Date Created: 20210331 Date Completed: 20210607 Latest Revision: 20210607
    • Publication Date:
      20240829
    • Accession Number:
      PMC8013829
    • Accession Number:
      10.1001/jamanetworkopen.2021.2612
    • Accession Number:
      33787913